



TO THE NATIONAL SECURITIES MARKET COMMISSION

Madrid, 20 December, 2019

In compliance with the disclosure obligations set out in article 227 of the Revised Text of the Securities Market Act, Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, "**ROVI**" or the "**Company**") informs the National Securities Market Commission of the following

PRICE-SENSITIVE INFORMATION

The Company's Board of Directors has passed the following resolutions on its own composition, which have taken effect after fulfilling the administrative requirements and having received [yesterday] the letter of acceptance of her appointment from the new director mentioned below:

- I.** To accept the resignation of Mr Enrique Castellón Leal from his position as a director and as a member of the Audit Committee and Nomination and Remuneration Commission, given that 12 years have elapsed since he was first appointed as a director of ROVI, which affects his classification as an independent external director. The Board has expressed its gratitude for Mr Castellón's valuable contribution to ROVI during his years on the Board.
- II.** To co-opt Ms Fátima Báñez García as an independent external director of the Company at the proposal of the Nominations and Remuneration Commission. The professional profile and biography of Ms Báñez may be found on the Company's corporate website (www.rovi.es).
- III.** To appoint Ms Fátima Báñez García as a member of the Audit Committee and Nominations and Remuneration Commission of ROVI.

- IV.** To appoint Mr Marcos Peña Pinto as the lead director to replace Mr Castellón, who was performing said function until he resigned as a member of the Board.

Mr Juan López-Belmonte Encina
Chief Executive Officer and General Manager
Laboratorios Farmacéuticos ROVI, S.A.



For more information:
Investor Relations (Tel: +34 91 244 44 22)
Marta Campos Martínez mcampos@rovi.es

ROVI appoints new independent director and lead director

Madrid, 20 December 2019 – The Board of Directors of Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”), at the proposal of the Nomination and Remuneration Commission, has co-opted Ms Fátima Báñez as a director of the company with the category of “independent external” director. The new director succeeds Mr Enrique Castellón Leal, who has resigned from his position because 12 years have elapsed since he was first appointed as a director of ROVI, which affects his classification as an independent external director. The Board has expressed its gratitude to Mr Castellón for his valuable contribution to ROVI during his years on the Board.

Subsequent to the resignation of Mr Castellón, the Board has appointed Mr Marcos Peña as the new independent lead director. Likewise, Ms Báñez has been appointed as a member of the Audit Committee and the Nomination and Remuneration Commission.

ROVI is a pharmaceutical company firmly committed to research and innovation and the development of human capital and talent. Thus, the company has reinforced its Board by including a professional of recognised prestige and extensive experience in talent management and commitment to people.

Fátima Báñez, who graduated in Law and Economic and Business Sciences from the *Universidad Pontificia de Comillas*, completed her education with postgraduate studies in Business Administration at the University of Harvard and the Leadership for Public Management Program at the IESE Business School. From December 2011 until June 2018, Ms Báñez held the position of Minister of Employment and Social Security of the Government of Spain and she was the interim Minister of Health, Social Services and Equality from August 2016 until November of the same year. Furthermore, the new director has extensive international experience, having represented the Spanish

government on the Employment, Social Policy, Health and Consumer Affairs Council of the EU (EPSCO) and at the G-20, Ibero-American Summits, the Organisation for Economic Cooperation and Development (OECD), the International Labour Organisation (ILO) and the International Employment Forum. Her complete curriculum vitae is available on ROVI's website (www.rovi.es).

After the inclusion of Ms Fátima Báñez, the Board has three executive directors, one proprietary director and three independents. Its composition is as follows: Mr Juan López-Belmonte López, Chair and proprietary director; Mr Juan López-Belmonte Encina, Chief Executive Officer and executive director; Mr Iván López-Belmonte Encina, First Deputy Chair and executive director; Mr Javier López-Belmonte Encina, Second Deputy Chair and executive director; Mr Marcos Peña Pinto, Independent Lead Director; Mr José Fernando de Almansa Moreno-Barreda and Ms Fátima Báñez, both of whom are independent directors.

About ROVI

ROVI is a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy France and Poland, and has a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, which is already marketed in 56 countries all over the world, should be highlighted. Likewise, in 2017, ROVI commenced the marketing of its in-house developed enoxaparin biosimilar in Europe. ROVI continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release with proven advantages. For more information, please visit www.rovi.es